Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.

Cytometry B Clin Cytom 2006 Jul;70(4):214-7

Department of Hematology and Laboratory of Experimental Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.

Chronic lymphocytic leukemia (CLL) is a disease with an extremely heterogeneous prognosis. Because of this and because of the lack of a truly effective therapy, treatment of CLL must be adapted to the individual risk of each patient. Over the last quarter of century, prognosis of patients with CLL has been based on clinical features. In the last few years a number of biological prognostic parameters have been identified. Among them, the expression of ZAP-70 in neoplastic B lymphocytes is increasingly being recognized as of paramount importance to predict outcome. Patients with a low percentage (<20%) of ZAP-70 positive neoplastic B lymphocytes have a much better prognosis that those with a higher proportion (>20%) of ZAP-70 positive neoplastic B lymphocytes.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.20131DOI Listing
July 2006
2 Reads

Publication Analysis

Top Keywords

chronic lymphocytic
8
neoplastic lymphocytes
8
lymphocytic leukemia
8
clinical features
4
features years
4
number biological
4
prognostic parameters
4
biological prognostic
4
years number
4
based clinical
4
patient quarter
4
risk patient
4
individual risk
4
quarter century
4
century prognosis
4
cll based
4
patients cll
4
parameters identified
4
zap-70 neoplastic
4
low percentage
4

Altmetric Statistics

References

(Supplied by CrossRef)

Rai et al.
Blood 1975

Binet et al.
Cancer 1981

Rozman et al.
Leukemia 1997

Molica et al.
Haematologica 2001

Mauro et al.
Blood 2000

Kyasa et al.
Am J Hematol 2003

Montserrat et al.
Ann Oncol 2004

Zent et al.
Curr Oncol Rep 2004

Döhner et al.
N Engl J Med 2000

Döhner et al.
J Mol Med 1999

Cuneo et al.
Leukemia 2004

Similar Publications